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Background 
C-reactive protein (CRP) is synthesized in the 
liver in response to interleukin and other cytokine 
polypeptides which are released from sites of 
inflammation.  Infections, burns, tissue necrosis, 
wounds, surgery, stress or psychiatric conditions, 
and atherosclerosis can precipitate the release of 
CRP.  CRP amounts are thought to be 
proportional to the extent of tissue damage.1,2 
High-sensitivity CRP tests (hs-CRP) are 
preferred over classic CRP testing due to their 
ability to detect CRP levels below 1 mg/L.2  
The possible beneficial effects of statins have 
been described for several diseases, including 
Alzheimer’s disease, multiple sclerosis, 
nonischemic cardiomyopathy, prevention of bone 
fractures, infection, and some types of cancer.  
The generalized anti-inflammatory action of the 
statins has been proposed as a possible 
explanation.3,4 
In the Pravastatin or Atorvastatin Evaluation 
and Infection Therapy – Thrombolysis in 
Myocardial Infarction 22 (PROVE IT – TIMI 22) 
trial comparing an aggressive LDL-lowering 
atorvastatin 80 mg regimen with a moderate LDL-
lowering pravastatin 40 mg regimen, improved 
cardiovascular outcomes for aggressive statin 
therapy were demonstrated.5  The Reversing 
Atherosclerosis with Aggressive Lipid Lowering 
(REVERSAL) trial, using the same statin 
regimen, identified a reduced rate of progression 
of atherosclerosis with the intensive lipid-
lowering atorvastatin regimen.6  Both studies 
revealed significant reductions in CRP levels with 
aggressive statin therapy.3,7 
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This study by Ridker et al was a substudy of 
PROVE IT – TIMI 22.  It consisted of 3,745 
participants representing 90% of the original study 
cohort.  PROVE IT – TIMI 22 was a randomized 
trial between November 2000 and February 2004 
which compared the effect of intensive statin 
therapy (atorvastatin 80 mg daily) with moderate 
statin therapy (pravastatin 40 mg daily) and of 
gatifloxacin and placebo on the risk of recurrent 
coronary events after acute coronary syndromes.5  
Members of the substudy population were alive 
and free of recurrent events 30 days after the 
study’s end.  Each participant had plasma 
measurements of both LDL cholesterol and hs-
CRP at baseline randomization, 30 days, four 
months, and at the end of the study.  The achieved 
levels of these two measures was defined as those 
obtained at the 30-day follow-up visit.  The study 
population was divided into quartiles based on the 
levels of achieved LDL cholesterol and achieved 
CRP.  The population was further divided on the 
basis of the approximate median achieved LDL 
cholesterol level (70 mg/dL) and the approximate 
median achieved CRP level (2 mg/L).  These 
values served as target levels for the study.  
Researchers evaluated whether the rates of events 
differed between patients with values above the 
median and those below the median.  
 
Results 
The levels of both LDL cholesterol and CRP 
were reduced by the statin therapy at the end of 30 
days.  Intensive atorvastatin therapy reduced LDL 
cholesterol levels to below 70 mg/dL and CRP 
levels to below 2 mg/L more effectively than 
moderate pravastatin therapy.  There was little 
evidence that either agent led to better clinical 
outcomes once target LDL cholesterol and CRP 
levels were achieved.  Achieving both of these 
target levels was of greater importance for event-
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free survival than was the type of statin therapy.  
The correlation (r) between achieved LDL 
cholesterol levels and achieved CRP levels was 
small (r = 0.16, P = 0.001).  Less than 3% of the 
variance in achieved CRP levels was explained by 
the variance in achieved LDL cholesterol.  
Recurrent myocardial infarctions or deaths in the 
study population were expressed as age-adjusted 







LDL > 70 4.0 0.008 
LDL < 70 2.7  
CRP > 2 3.9 0.006 
CRP < 2 2.8  
LDL > 70 & 
CRP > 2 
4.6 <0.001 
LDL < 70 & 
CRP > 2 
3.1  
LDL > 70 & 
CRP< 2 
3.2  
LDL < 70 & 
CRP< 2 
2.4  
CRP > 1 3.8 <0.001 
CRP < 1 2.1  
LDL > 70 & 
CRP > 1 
4.5 <0.001 
LDL < 70 & 
CRP > 1 
3.1  
LDL > 70 & 
CRP< 1 
2.3  
LDL < 70 & 
CRP< 1 
1.9  
*LDL units = mg/dL, CPR units = mg/L 
**P values for comparison between two or 
among four groups 
 
Author Conclusions 
Despite resultant levels of LDL cholesterol, 
patients who had low CRP levels after statin 
therapy had better clinical coronary outcomes than 
those with higher CRP levels.  Monitoring CRP 
and LDL cholesterol should be used in lowering 
cardiovascular risks with statin therapy.  
 
Commentary 
This substudy of PROVE IT – TIMI 22 offers 
the first evidence suggesting that CRP is an 
independent factor useful in monitoring and 
adjusting statin therapy.  Event rates were similar 
for LDL < 70 mg/dL and CRP > 2 mg/L 
compared with LDL > 70 mg/dL and CRP < 2 
mg/L at 3.1 vs. 3.2 events per 100 patient-years, 
respectively.  Furthermore, event rates for LDL < 
70 mg/dl and CRP > 1 mg/L were reported to be 
3.1.  Whereas, event rates for LDL > 70 mg/dL 
and CRP < 1 mg/L were 2.3.  When LDL < 70 
mg/dL and CRP < 1 mg/L, event rates were the 
lowest reported in the study.8   
In a 502 patient substudy of the Reversal of 
Atherosclerosis with Aggressive Lipid Lowering 
(REVERSAL) study7, the extent of both LDL 
cholesterol lowering and CRP lowering using the 
same statins and doses as in PROVE IT – TIMI 22 
were associated with reduced progression of 
atheroma volume.  Intensive atorvastatin therapy 
(80 mg per day) reduced the atheroma progression 
rate more than did moderate pravastatin therapy 
(40 mg per day).  With reductions in LDL 
cholesterol and CRP both greater than their 
respective median percent changes, total atheroma 
volume showed the greatest reduction (-1.98 
mm3).  As in the study by Ridker et al,8 
correlation between reductions in LDL cholesterol 
and reductions in CRP were weak (r = 0.13, P = 
0.005).  These data indicate that statin reductions 
in CRP are independent from statin reductions in 
LDL cholesterol.  These authors conclude that 
their findings suggest that the level of CRP may 
be an important therapeutic target.  They do not 
believe that their data is sufficient to recommend 
routine measurements of CRP alone for statin 
therapy modification.   
The substudy data of the PROVE IT – TIMI 22 
trial supports the aggressive use of statins to 
achieve target levels of both LDL cholesterol and 
CRP for reduction of coronary events in post 
acute coronary syndrome patients [Evidence level 
A; high-quality RCT].8 
Guidelines currently do not recommend 
routine use of CRP as a screening test for the 
general population.  Rather, it is recommended for 
detecting enhanced absolute risk in those where 
multiple risk factor scoring projects a ten year 
coronary heart disease risk in the range of 10% to 
20%.9  The American Heart Association (AHA) in 
their 2004 Scientific Statement on Preventing 
Cancer, Cardiovascular Disease, and Diabetes 
identify hs-CRP as an additional factor that may 
help in the prognostification of risk.10
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Further studies will be needed to answer the 
question whether CRP alone will be useful for 
initiation and modulation of statin therapy.   
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
 
Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based 
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